Discover
LGVN
Longeveron Inc.
2.49
2 x 4.98
2 x 8.70
bid
ask
-
0.22
8.12%
2 @ 04:09 AM
2.50 +0.01 (0.40%)
| Ytd | -50.79% | |
| 1y | -67.66% |
2.30
day range
2.75
2.30
52 week range
12.30
| Open | 2.73 | Prev Close | 2.71 | Low | 2.30 | High | 2.75 | Mkt Cap | 7.94M |
| Vol | 527.17K | Avg Vol | 81.03K | EPS | -10.00 | P/E | N/A | Forward P/E | -1.16 |
| Beta | 0.35 | Short Ratio | 2.03 | Inst. Own | 3.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 6.75 | 200-d Avg | 7.19 | 1yr Est | 8.88 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.53 | -0.34 | 0.19 | 35.85% |
| 2024-08-14 | 2024-06 | -1.03 | -1.83 | -0.8 | -77.67% |
| 2024-08-14 | 2024-06 | -1.03 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -2.01 | -1.61 | 0.4 | 19.90% |
| 2024-05-14 | 2024-03 | -2.01 | N/A | N/A | N/A |
| 2024-02-27 | 2023-12 | -2.1 | -2.5 | -0.4 | -19.05% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-05 | Roth MKM | Upgrade | Buy | |
| 2024-11-25 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-27 | Maxim Group | Upgrade | Buy | Buy |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-14 | AGAFONOVA NATALIYA | Officer | 163.13K | Stock Award(Grant) |
| 2024-12-01 | BALUCH KHOSO | Director | 23.75K | Sale |
| 2024-08-14 | HARE JOSHUA M | Officer, Director and Beneficial Owner | 727.05K | Stock Award(Grant) |
| 2024-08-14 | HARE NEIL E | Director | 30.25K | Stock Award(Grant) |
| 2024-08-14 | HASHAD MOHAMED WA'EL AHMED | Chief Executive Officer | 90.37K | Stock Award(Grant) |
| 2024-05-09 | KENDER RICHARD N | Director | 16.00K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Geode Capital Management, LLC | 128.95K | 228.24K | 0.97% |
| 2024-09-29 | Vanguard Group Inc | 44.98K | 79.62K | 0.34% |
| 2024-09-29 | Capital Investment Advisory Services, LLC | 26.53K | 46.95K | 0.20% |
| 2024-09-29 | State Street Corporation | 15.18K | 26.87K | 0.11% |
| 2024-09-29 | Creative Planning | 11.20K | 19.82K | 0.08% |
| 2024-09-29 | Blackrock Inc. | 10.02K | 17.73K | 0.08% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 72.20K | 127.79K | 0.54% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 44.98K | 79.62K | 0.34% |
| 2024-10-30 | Fidelity Total Market Index Fund | 24.14K | 42.72K | 0.18% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 17.09K | 30.24K | 0.13% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 3.57K | 6.32K | 0.03% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2024-03-27 |